Indoleacetylglutamine Pathway Is a Potential Biomarker for Cardiovascular Diseases
Cardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality. Metabolomics allows for the identification of important biomarkers for CVDs, essential for early detection and risk assessment. This cross-sectional study aimed to identify novel metabolic biomarkers associated...
Saved in:
| Main Authors: | Khaled Naja, Najeha Anwardeen, Mashael Al-Shafai, Mohamed A. Elrayess |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/15/3/377 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lipid Subclasses Differentiate Insulin Resistance by Triglyceride–Glucose Index
by: Khaled Naja, et al.
Published: (2025-05-01) -
Advancements in precision medicine: multi-omics approach for tailored metformin treatment in type 2 diabetes
by: Najeha Rizwana Anwardeen, et al.
Published: (2024-11-01) -
N-Lactoyl amino acids as metabolic biomarkers differentiating low and high exercise response
by: Maha Sellami, et al.
Published: (2024-12-01) -
Uncovering potential biomarkers and metabolic pathways in systemic lupus erythematosus and lupus nephritis through integrated microbiome and metabolome analysis
by: Siyun Cheng, et al.
Published: (2025-05-01) -
Gut microbiota-derived metabolite phenylacetylglutamine in cardiovascular and metabolic diseases
by: Wan Chen, et al.
Published: (2025-07-01)